Getting better without age: New insights into the diabetic heart

Circulation Research

Volumn 92, Issue 7, 2003, Pages 704-706

  Kass, David A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AGE; Collagen; Diabetes; Heart; RAGE

Indexed keywords

4,5 DIMETHYL 3 PHENACYLTHIOZOLIUM CHLORIDE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; APOLIPOPROTEIN E; CARBONYL DERIVATIVE; CHLORIDE; COLLAGEN; CYTOKINE; GLUCOSE; GROWTH FACTOR; HEMOGLOBIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIGAND; METAL ION; OXIDIZING AGENT; PROTEIN; PROTEIN P21; PYRIDOXAMINE; RADICAL; RECEPTOR; SCHIFF BASE; STREPTOZOCIN; TISSUE GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALINE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; BETA CHAIN; CARBOHYDRATE ANALYSIS; CHELATION; CLINICAL TRIAL; COLOR; CROSS LINKING; DIABETES MELLITUS; DISEASE MODEL; EDITORIAL; ENZYME ACTIVITY; GLOMERULOPATHY; GLYCATION; GLYCOSYLATION; HUMAN; KIDNEY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UPREGULATION; VASCULAR DISEASE;

ANIMALS; COLLAGEN; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, IMMUNOLOGIC; THIAZOLES;

EID: 0037453588     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000069362.52165.C9     Document Type: Editorial

References (34)

1. Maillard L, Gautier MA. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Seances Acad Sci 111. 1912;154:66-68.
2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
3. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976;295:417-420.
4. Iyer SP, Hart GW. Dynamic nuclear and cytoplasmic glycosylation: enzymes of o-GlcNAc cycling. Biochemistry. 2003;42:2493-2499.
5. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and o-GlcNAc. Science. 2001;291:2376-2378.
6. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001;56:1-21.
7. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21:3-12.
8. Facchiano F, Lentini A, Fogliano V, Mancarella S, Rossi C, Facchiano A, Capogrossi MC. Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo. Am J Pathol. 2002;161:531-541.
9. Badenhorst D, Maseko M, Tsotetsi OJ, Naidoo A, Brooksbank R, Norton GR, Woodiwiss AJ. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res. 2003;57:632-641.
10. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, Mizrahi J, Schalkwijk CG, Thorpe SR, Baynes JW, Bijlsma JW, Lafeber FP, TeKoppele JM. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002;46:114-123.
11. Mott JD, Khalifah RG, Nagase H, Shield CF III, Hudson JK, Hudson BG. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 1997;52:1302-1312.
12. Sakata N, Meng J, Jimi S, Takebayashi S. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis. 1995;116:63-75.
13. Picklo MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol. 2002;184:187-197.
14. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949-955.
15. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38:S100-S106.
16. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu FT, Di Mario U. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. 2001;15:2471-2479.
17. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest. 1991;87:432-438.
18. Chen J, Brodsky SV, Goligorsky DM, Hampel DJ, Li H, Gross SS, Goligorsky MS. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res. 2002;90:1290-1298.
19. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology. 2001;142:1760-1769.
20. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C β2 activation and diabetes. Diabetes. 2002;51:2709-2718.
21. Mizutani K, Ikeda K, Tsuda K, Yamori Y. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rate. J Hypertens. 2002;20:1607-1614.
22. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation. 1996;93:1905-1912.
23. Corman B, Duriez M, Poitevin P, Heudes D, Bruneval P, Tedgui A, Levy BI. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA. 1998;95:1301-1306.
24. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology. 2002;143:4907-4915.
25. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem. 2001;276:48967-48972.
26. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159:513-525.
27. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2001;21:905-910.
28. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827-2835.
29. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A. 2000;97:2809-2813 [erratum Proc Natl Acad Sci U S A. 97:5679].
30. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, Vasan S, Wagle DR, Ulrich P, Brines M, Wuerth JP, Cerami A, Lakatta EG. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A. 2001;98:1171-1175.
31. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464-1470.
32. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92:785-792.
33. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 2002;55:76-82.
34. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest. 1997;99:1016-1027.